146 related articles for article (PubMed ID: 12439220)
1. Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies.
Blanco JG; Edick MJ; Hancock ML; Winick NJ; Dervieux T; Amylon MD; Bash RO; Behm FG; Camitta BM; Pui CH; Raimondi SC; Relling MV
Pharmacogenetics; 2002 Nov; 12(8):605-11. PubMed ID: 12439220
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia.
Larson RA; Wang Y; Banerjee M; Wiemels J; Hartford C; Le Beau MM; Smith MT
Blood; 1999 Jul; 94(2):803-7. PubMed ID: 10397748
[TBL] [Abstract][Full Text] [Related]
3. The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia.
Bolufer P; Collado M; Barragán E; Cervera J; Calasanz MJ; Colomer D; Roman-Gómez J; Sanz MA
Haematologica; 2007 Mar; 92(3):308-14. PubMed ID: 17339179
[TBL] [Abstract][Full Text] [Related]
4. NAD(P)H:quinone oxidoreductase 1 null genotype is not associated with pediatric de novo acute leukemia.
Sirma S; Agaoglu L; Yildiz I; Cayli D; Horgusluoglu E; Anak S; Yuksel L; Unuvar A; Celkan T; Apak H; Karakas Z; Devecioglu O; Ozbek U
Pediatr Blood Cancer; 2004 Oct; 43(5):568-70. PubMed ID: 15382274
[TBL] [Abstract][Full Text] [Related]
5. Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia.
Bolufer P; Collado M; Barragan E; Calasanz MJ; Colomer D; Tormo M; González M; Brunet S; Batlle M; Cervera J; Sanz MA
Br J Haematol; 2007 Feb; 136(4):590-6. PubMed ID: 17367411
[TBL] [Abstract][Full Text] [Related]
6. Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies.
Woo MH; Shuster JJ; Chen C; Bash RO; Behm FG; Camitta B; Felix CA; Kamen BA; Pui CH; Raimondi SC; Winick NJ; Amylon MD; Relling MV
Leukemia; 2000 Feb; 14(2):232-7. PubMed ID: 10673738
[TBL] [Abstract][Full Text] [Related]
7. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose.
Dally H; Edler L; Jäger B; Schmezer P; Spiegelhalder B; Dienemann H; Drings P; Schulz V; Kayser K; Bartsch H; Risch A
Pharmacogenetics; 2003 Oct; 13(10):607-18. PubMed ID: 14515059
[TBL] [Abstract][Full Text] [Related]
8. Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.
Gervasini G; García-Martín E; Ladero JM; Pizarro R; Sastre J; Martínez C; García M; Diaz-Rubio M; Agúndez JA
BMC Cancer; 2007 Jul; 7():118. PubMed ID: 17605821
[TBL] [Abstract][Full Text] [Related]
9. The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia.
Barragan E; Collado M; Cervera J; Martin G; Bolufer P; Roman J; Sanz MA
Leuk Res; 2007 Jul; 31(7):947-53. PubMed ID: 17118447
[TBL] [Abstract][Full Text] [Related]
10. Association of CYP3A4 genotype with detection of Vgamma/Jbeta trans-rearrangements in the peripheral blood leukocytes of pediatric cancer patients undergoing chemotherapy for ALL.
Lopes LF; Piccoli Fde S; Paixão VA; Latorre Mdo R; Camargo Bd; Simpson AJ; Caballero OL
Leuk Res; 2004 Dec; 28(12):1281-6. PubMed ID: 15475069
[TBL] [Abstract][Full Text] [Related]
11. Polymorphism analysis of CYP3A5 in myeloid leukemia.
Liu TC; Lin SF; Chen TP; Chang JG
Oncol Rep; 2002; 9(2):327-9. PubMed ID: 11836601
[TBL] [Abstract][Full Text] [Related]
12. Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina.
Semiz S; Dujić T; Ostanek B; Prnjavorac B; Bego T; Malenica M; Mlinar B; Marc J; Causević A
Med Glas (Zenica); 2011 Feb; 8(1):84-9. PubMed ID: 21263403
[TBL] [Abstract][Full Text] [Related]
13. Effects of cytochrome P450 family 3 subfamily A member 5 gene polymorphisms on daunorubicin metabolism and adverse reactions in patients with acute leukemia.
Huang Z; Wang J; Qian J; Li Y; Xu Z; Chen M; Tong H
Mol Med Rep; 2017 Jun; 15(6):3493-3498. PubMed ID: 28440407
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases.
Jin M; Gock SB; Jannetto PJ; Jentzen JM; Wong SH
J Anal Toxicol; 2005 Oct; 29(7):590-8. PubMed ID: 16419387
[TBL] [Abstract][Full Text] [Related]
15. Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients.
Żochowska D; Wyzgał J; Pączek L
Ann Transplant; 2012; 17(3):36-44. PubMed ID: 23018254
[TBL] [Abstract][Full Text] [Related]
16. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Lepper ER; Baker SD; Permenter M; Ries N; van Schaik RH; Schenk PW; Price DK; Ahn D; Smith NF; Cusatis G; Ingersoll RG; Bates SE; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
Clin Cancer Res; 2005 Oct; 11(20):7398-404. PubMed ID: 16243813
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphism of NAD(P)H:quinone oxidoreductase is associated with an increased risk of infant acute lymphoblastic leukemia without MLL gene rearrangements.
Lanciotti M; Dufour C; Corral L; Di Michele P; Pigullo S; De Rossi G; Basso G; Leszl A; Luciani M; Lo Nigro L; Micalizzi C; Valsecchi MG; Biondi A; Haupt R
Leukemia; 2005 Feb; 19(2):214-6. PubMed ID: 15618957
[TBL] [Abstract][Full Text] [Related]
18. The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia.
Borst L; Wallerek S; Dalhoff K; Rasmussen KK; Wesenberg F; Wehner PS; Schmiegelow K
Eur J Haematol; 2011 Jun; 86(6):477-83. PubMed ID: 21418106
[TBL] [Abstract][Full Text] [Related]
19. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations.
Gervasini G; Vizcaino S; Gasiba C; Carrillo JA; Benitez J
Ther Drug Monit; 2005 Dec; 27(6):819-21. PubMed ID: 16306861
[TBL] [Abstract][Full Text] [Related]
20. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
